COPD

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

Providers who care for patients with asthma or COPD need to be aware of the increased risk of rheumatoid arthritis.

The new low nicotine products contain 95% less nicotine than the top 100 cigarette brands in the US, according to 22nd Century Group.

A new guidance breaks ground as the first of its kind to assist physicians in screening for, and treating, vaping-associated respiratory disease syndrome.

New follow-up data shows older patients with COPD characterized by high blood eosinophil counts may benefit from the biologic.

New VDAART follow-up findings show at-risk children are not safer from asthma or recurrent wheeze when their mother takes prenatal vitamin D.

New research into the role of legislation on vaping use shows certain laws may be more effective than others.

New cohort data shows significantly worsened respiratory symptoms among patients with comorbid cough and COPD.

The FDA will rule on the type 2 inflammation-targeting biologic for another indication this May.

New data shows the market-controlling e-cigarette product nearly doubled its rate of young adult users in just 1 year.

New findings show patients with HDHPs are more likely to skip inhaler therapy due to costs, and are therefore more frequently hospitalized.

A long-term comparison trial with smokers motivated to quit show the combination of alternative nicotine products could slightly and safely improve cessation.

A comparison of virtual training to in-person education showed the former was noninferior to the latter among patients with asthma or COPD.

The US Food and Drug Administration has announced a comprehensive ban on flavored, pod-based e-cigarette cartridges earlier this week.

A re-prioritization of disease monitoring and screening could help physicians better understand how one of the greatest killers in the US could be combated.

An assessment of metoprolol in older patients with COPD had to be discontinued after treated patients reported a greater rate of hospitalization due to exacerbations.

A new cohort analysis shows hospitalized smokers are not at complication risk due to the perioperative therapy.

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.

A new study shows that bronchoscopy practice, procedure, and tools vary by facility, and in assessment duration.

A study comparing the LAMA/LABA to monotherapy found patients without prior ICS treatment benefitted significantly, regardless of disease severity or symptoms.

A comparative cohort found inpatient and outpatient costs, both for respiratory and all-cause conditions, were less per month for patients on the antifibrotic.

New findings from the phase 3 trial show budesonide/ glycopyrrolate/ formoterol fumarate significantly reduces exacerbations among patients with no exacerbation history, compared to dual therapies.

From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.

How the LAMA therapy manages one of the integral facets of COPD care.

While one disease is benefitting from advancing digital screening measures, the other has a standard therapy which could provide benefit to both.

A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.

How should physicians navigate the public belief that vaping is less harmful than cigarette smoking?